GIRINDUS : America, Inc. Appoints Dr. Edward Huber as Director - Analytical Development and Quality Control

Girindus, a service provider to the pharmaceutical industry and a leading manufacturer of therapeutic oligonucleotides, is pleased to announce the appointment of Dr. Edward Huber as Director - Analytical Development & QC.

Dr. Huber will provide managerial and technical leadership in the areas of analytical development and quality control. He brings to Girindus 30 years of pharmaceutical experience in the area of structural elucidation, separations sciences, and the development and validation of analytical methods for the characterization and control of Active Pharmaceutical Ingredients (API) and finished dosage forms.

'We are very pleased to have Ed on the Girindus leadership team,' said Dr. Mark Laskovics, Girindus President and COO. 'We welcome his extensive expertise in both the technical and managerial areas of QC / Analytics which will reinforce the high quality and technical standards Girindus has achieved to date'.

Dr. Huber received a BS degree from Xavier University and MS and PhD Degrees in Analytical Chemistry from the University of Cincinnati. Ed has demonstrated leadership qualities in both industry and the chemical community. Dr. Huber has held positions of increasing responsibility in analytical chemistry at Marion Merrell Dow, Hoechst Marion Roussel, Aventis and Patheon. He is author or co-author of over 50 scientific publications in peer-reviewed journals and was most recently Director of Analytical Development within Patheon's Pharmaceutical Development Services group.

Language:		English
Company:		Girindus AG
		Buchenallee 20
		51427 Bergisch Gladbach
		Deutschland
Internet:		www.girindus.com

Girindus AG, Member of Solvay Organics
Markus Georgi, [phone]
Head of Investor Relations
or
Girindus America, Inc., Member of Solvay Organics
Kathryn L. Ackley, Ph.D., [phone]
Director of Operations